Cell Culture Influenza Vaccines: The current status
|
|
- Herbert Woods
- 7 years ago
- Views:
Transcription
1 Cell Culture Influenza Vaccines: The current status Han van den Bosch, Amsterdam, The Netherlands 7th WHO Meeting on Influenza Vaccine Technology Transfer to Developing Country Manufacturers. Dubai, March 2014
2 Statement The presentation contains publicly available information only, The presentation gives a limited overview of the subject, and does not intend to be complete in every detail and in all options, Examples given about production systems and issues do not provide a guarantee about the performance of a certain system.
3 Advantages of cell-culture-derived influenza vaccines (1) Permits growth of all influenza viruses H3N2 strains are difficult to isolate in eggs No need for egg adapted High Growth Reassortants Available on short notice during any season Lead time shorter as compared to egg supply No need for embryonated chicken eggs from biosecure flocks Not enough chickens may be available in case of avian flu outbreak Easier logistics Less waste disposal Maintained in aseptic closed environment during upstream and downstream
4 Advantages of cell-culture-derived influenza vaccines (2) Reduced risk of contamination during production More controlled and consistent production process Higher purity of starting material Safe whole virus vaccines feasible Animal-component-free production feasible Reduces vaccine production time Might provide broader immunity to influenza variants Egg passaging might induce adaptive changes for growth in eggs Safe for individuals with allergy to eggs Allows for multipurpose facility use (other vaccines, MAbs and other therapeutic proteins) W.P. Glezen (2011), The Lancet 377: P.D. Minor et al (2009), Vaccine 27:
5 Marketing Authorization of cell-culture seasonal IIV 2001: Influvac TC, Solvay / Abbott, MDCK-a, EU Discontinued after acquisition by Abbott 2007: Optaflu, Novartis, MDCK-s, EU 2012: Flucelvax, Novartis, MDCK-s, USA 2010: Preflucel, Baxter, Vero, EU 2013: FluBlok, Protein Sciences, rec.ha in Baculo / SF9 (insect cells), USA Multiple (Pre-)Pandemic versions
6 Ongoing cell culture (P)IIV developments GSK (EB66, Valneva / Vivalis) Kaketsuken (+GSK) Sanofi Pasteur (discontinued PerC6) Crucell / J&J (PerC6) Takeda (+Baxter, Vero) Kitasato Daiichi Sankyo (MDCK)
7 Cell culture (P)LAIV developments MedImmune / AstraZeneca (MDCK) Halted after FDA requirements? (Wendy Wolfson, Nature Biotechnology 28, 115 (2010) Nobilon / Merck (MDCK, NOBI) Discontinued after acquisition by Merck (2010) Green Hills Biotech (Vero) Ongoing Others at earlier pre-clinical stages of development?
8 WHO Tables on clinical evaluation of influenza vaccines Number (%) of trials mentioned: VACCINE SUBSTRATE EGGS SUBSTRATE CELLS IIV (8%) LAIV 47 0 (0%) PIIV (12%) PLAIV 25 3 (11%)
9 Barriers / Challenges for cell culture influenza vaccines Regulatory Technical / Manufacturing Cell choice Production system Purification Yields Reproducibility & Repeatibility Stability of Product Timelines Financial Development costs Investments and Cost of Goods (CoG)
10 Regulatory WHO Guidelines for National Regulatory Authorities (NRAs)
11 Regulatory: Guidelines, Directives, Guidance
12 Regulatory: important cell aspects to consider Mammalian or avian Suspension or adherent Source and record / passage history (TSE) Adventitious agents Animal Component Free (incl. trypsin and benzonase) Stability at passaging (end-of-production passage) Suitability for production Tumorgenicity (living cells) Oncogenicity (host cell DNA remnants) Risk assessment
13 Technical / Manufacturing aspects Cell choice Production system ( upstream, USP) Purification ( downstream, DSP) Yields Reproducibility & Repeatibility (multiple virus strains) Stability of Product / Formulation Timelines
14 Cell choice MDCK, Vero, PerC6, EB66, or Other / New Adherent, or Suspension Suspension cells easier, higher yields, higher purity, lower CoG Seed production (MCB, WCB), Characterization and Sanitation: Tumorgenicity, Oncogenicity, Adventitious Agents, Identity, Stability
15 Virus seed preparation, adaptation from egg to cell substrate may be necessary for wildtype viruses, HGRs and LAIV reassortants: HA titer 0 14 eggs TC Passages
16 Production System; Roller bottle RollerCell40
17 Bioreactor Steel (Multi-Use, Fixed Piping) Modes: Suspension cells, Microcarrier, Perfusion
18 Disposable Bioreactors (Single-Use) Xcellerex XDR ( L) WAVE ( L
19 CellSTACK / Cell-Factory Disposable (Single-Use)
20 icellis : fixed-bed, high cell-density, perfusion bioreactor (Single-Use, disposable) 4RB 20RB 100RB 600RB 3000RB 4RB 20RB 40L 200L 1000L 4RB 20RB icellis 500
21 STAINLESS STEEL VS SINGLE USE INVESTMENT VS OPERATIONAL COSTS COGS/DOSE INVESTMENT 300 Stainless Steel facility 200 Level of investment icellis system similar to single-use approach, BUT Single Use facility 20 increase of production capacity LVM HVM PRODUCTION CAPACITY / YEAR Reduction of CoGS enabling affordability of biologics SU facility Univercells facility LVM HVM UNIVERCELLS
22 Typical USP+DSP production process IIV (whole virion, suspension MDCK) Grow cells in fermentor (2-3 days) Virus inoculation Virus harvest (3-5 days) Clarification by low speed centrifugation Filtration Inactivation by BPL DNA removal Ultra Filtration Removal of debris by precipitation Sucrose gradient Sterile filtration Concentration/Dialysis Adding stabilizer Blend vaccine J.G.M. Heldens. Mammalian cells for influenza vaccine production; comparison of various systems. Visiongain, London UK, May
23 Challenges: > Sucrose gradient Gradient from 0 55% Amount of virus determined per batch Separation of virus at 42 % sucrose, and HA sucrose sucrose % HA MDCK host cell protein at 30% sucrose fraction > Sterile filtration (220nm) Particle size: Virus 150nm Others nm protein concentration total protein concentration (µg/ml) MDCK protein concentration (µg/ml) fraction Antigen recovery over the whole process only 2-6% 50% antigen loss on sucrose gradient, and 50% loss on sterile filtration
24 Process adaptations IIV (whole virion) Grow cells in fermentor (2-3 days) Virus inoculation Virus harvest (3-5 days) Clarification by low speed centrifugation Filtration Inactivation by BPL DNA removal Ultra Filtration Removal of debris by precipitation Sucrose gradient Sterile filtration Concentration/Dialysis Adding stabilizer Blend vaccine Adapted Grow cells in fermentor (2-3 days) Virus inoculation Virus harvest (3-5 days) Clarification by high speed centrifugation Inactivation by BPL DNA removal Filtration Sterile filtration Concentration/Dialysis Adding stabilizer Blend vaccine
25 Summary adapted production IIV (whole virion, MDCK suspension, NIBRG14/H5N1 example) Robust scalable process HA yield between 8 and 10 > 95% removal total protein > 90% removal host cell protein > 90% removal DNA Antigen / 2000L NIBRG14 Batch 1 NIBRG14 Batch 2 NIBRG14 Batch gram 5.15 gram 4.64 gram NIBRG14 Antigen recovery 50 % gram antigen / 2000L
26 LAIV upstream production on adherent MDCK cells Wild type / high growth reassortant vs. cold adapted reassortant
27 Typical production process LAIV on adherent MDCK cells Production wt virus seeds, reassortment Reassortant virus seeds Grow cells on cell cube (2-3 days) Virus inoculation Virus harvest (3-5 days) Clarification by filtration DNA removal Concentration/Dialysis Adding stabilizer Blend vaccine 1 day
28 Example production LAIV on adherent MDCK cells Human Influenza A44/Brisbane/59/2007 (H1N1) Human Influenza A44/Brisbane/10/2007 (H3N2) Human Influenza B56/Brisbane/60/2008 Infectious titer Infectious Titer expressed in log10 TCID50/ml Viral Harvest Infectious titer Concentrate > Yield critical! > 98% removal total protein > 90% removal DNA
29 MedImmune LAIV-MDCK meeting VRBPAC (2008) (Vaccines and Related Biological Products Advisory Committee, FDA)
30 MedImmune LAIV-MDCK meeting VRBPAC (2008)
31 Summary, Cell Culture Influenza Vaccines Regulatory requirements and pathway should be clear for cell characterization (EMA, FDA, NRA) Use existing approved cell line if feasible (costs, time, IP) Suspension cells prefered over adherent cells Easier process, higher yield and purity of harvest, lower cost Different virus substrates require different DSP procedures Different virus strains may require adapted process parameters Production system hardware: steel (higher investment, lower exploitation costs) or disposable (lower investment, higher exploitation costs; increased flexibility) Need for not-egg-passaged vaccine seed viruses THANKS
Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationVaccine Production Strategies: Ensuring Alignment and Sustainability
Vaccine Production Strategies: Ensuring Alignment and Sustainability Second WHO Consultation on Global Action Plan for Influenza Vaccines (GAP-II) Robert W Malone, MD, MS Consulting, Vaccines and Biologicals
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationRecombinant protein vaccines produced in insect cells
Recombinant protein vaccines produced in insect cells Manon M.J. Cox Hong Kong 25JAN2013 Flublok BREAKING NEWS 16JAN2013 FDA approves Flublok for the prevention of influenza in adults 18-49 years old The
More informationVaccination policy, vaccine development and manufacturing in Japan. Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken
Vaccination policy, vaccine development and manufacturing in Japan Yoichiro Kino, Ph.D Executive Managing Director Kaketsuken Background of KAKETSUKEN Organization Name The ChemoSeroTherapeutic Research
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationCatching the Flu: A Photo Essay
May 2006 Catching the Flu: A Photo Essay As it tests a new way of making vaccines, TechnoVax is targeting the deadly 1918 flu virus. By Stephan Herrera (MIT Technology Review) Jose Galarza is the CEO of
More informationRECOMMENDATIONS FOR PRODUCTION AND CONTROL OF INFLUENZA VACCINE (INACTIVATED) Introduction General considerations
1 WHO Technical Report Series No. ANNEX 3 RECOMMENDATIONS FOR PRODUCTION AND CONTROL OF INFLUENZA VACCINE (INACTIVATED) Introduction General considerations Page Part A Manufacturing recommendations A1
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationA Human Designer cell Line Providing a Pandemic Proof Platform for the Manufacturing of Safe Influenza Vaccines
PER.C6 A Human Designer cell Line Providing a Pandemic Proof Platform for the Manufacturing of Safe Influenza Vaccines Fons March 26, 1918-1919 Flu Pandemic ~30 MillionDeaths The Devil in Enveloped virions
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationGuidance for Industry
Guidance for Industry Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications Additional copies
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationWorkshop on process validation
Workshop on process validation CMC Strategy Forum Europe 2013 EBE Process validation satellite session Pragues, 06/05/2013 Kowid Ho Scope / background Process evaluation/validation of biotechnology derived
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationOverview of Upstream and Downstream Processing of Biopharmaceuticals
Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationMixing, mass transfer and bioprocess scaling up and down in new generation single-use bioreactors. Nico Oosterhuis CELLution Biotech
Mixing, mass transfer and bioprocess scaling up and down in new generation single-use bioreactors Nico Oosterhuis CELLution Biotech Questions of today Mixing and mass transfer in single use bioreactor:
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION At the forefront of innovation in vaccines & monoclonal antibodies April 2012 VIVALIS MODEL A unique positioning in fast growing markets Corporate Overview Vivalis in a snapshot
More informationPandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic
Pandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic Nancy J. Cox, Ph.D. Director, Influenza Division Director WHO Collaborating Center for Influenza NCIRD, Centers for Disease
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationNext-Generation Facilities for Monoclonal Antibody Production
Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationBIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM
BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM FROM ORIGINATOR THROUGH COMPARABILITY TO MARKET STREAMLINE YOUR R&D, REGULATORY, ANALYTICAL, AND CLINICAL NEEDS WITH ONE PROVIDER The development pathway of
More informationUna nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp
Una nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp XLVIII LECCIÓN CONMEMORATIVA JIMÉNEZ DÍAZ Madrid Mayo 2016 Juan C Ramírez CSO/CTO Non-Disclosure/Confidentiality
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationA new, integrated, continuous purification process template for monoclonal antibodies
A new, integrated, continuous purification process template for monoclonal antibodies Alex Xenopoulos* Alison Dupont, Christopher Gillespie, Ajish Potty, Michael Phillips Processing Technologies Merck
More informationCustomer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical
Customer Application Brief Bioprocess, Biologicals, & Pharmaceutical Filtration Processes Applied in Therapeutic Monoclonal Antibody Production Introduction Monoclonal antibodies were among the first biotechnology
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. Introduction Annual influenza epidemics are associated with substantial morbidity and mortality, especially in elderly and in those with underlying diseases. Although in healthy
More informationUse of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development
Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM
More informationRecommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral)
FINAL ENGLISH ONLY Recommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral) Replacement of: TRS 904, Annex 1 and Addendum TRS 910, Annex 1 World Health
More informationViral Safety of Plasma-Derived Products
Viral Safety of Plasma-Derived Products SLIDE 1 This presentation will cover viral validation studies for plasma-derived products. FDA requires that the manufacturing process for biopharmaceutical products
More informationValneva Reports Annual Results 2014 Lyon (France), March 20, 2015
Valneva Reports Annual Results 2014 The company announces a significant improvement to its EBITDA and a strong reduction of its net loss compared to prior-year pro forma result - Significant progress on
More informationImplementation of Advanced Chromatography techniques to Mitigate Purification Concerns in Bispecific Monoclonal Antibody Manufacturing
www.beroe- WHITEPAPER December 2012 inc.com Implementation of Advanced Chromatography techniques to Multi Column Solvent Gradient Purification or MCSGP chromatography process is a better solution to Bispecific
More informationFDA Update on the H1N1 Flu Vaccine and Antiviral Medications
FDA Update on the H1N1 Flu Vaccine and Antiviral Medications Beth Fabian Fritsch, R.Ph., M.B.A. Commander, U.S. Public Health Service Health Programs Coordinator Office of Special Health Issues Food and
More informationSingle-Use Bioreactors Meeting BioPharma Needs for Lower Operating Cost and Faster Time to Market
Single-Use Bioreactors Meeting BioPharma Needs for Lower Operating Cost and Faster Time to Market White Paper White Paper Single-use bioreactors meeting biopharma needs for lower operating cost and faster
More informationGuidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
More informationGlaxoSmithKline Pandemic Influenza Portfolio
GlaxoSmithKline Pandemic Influenza Portfolio Schladminger Gesundheitsgespräche 06. June 2009 Responding to the Pandemic Influenza Threat - WHO Recommended Strategic Actions Non-pharmacological measures
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationWHO Technology Transfer Initiative: supporting grantees through the next phase
7th Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers WHO Technology Transfer Initiative: supporting grantees through
More informationRADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationFDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting September 19, 2012
FDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting September 19, 2012 Cell Lines Derived from Human Tumors for Vaccine Manufacture 1 Table of Contents Cell Lines
More informationControl of Newcastle and Infectious Bursal diseases in Poultry: Vaccines, Vaccination and Bio security
Control of Newcastle and Infectious Bursal diseases in Poultry: Vaccines, Vaccination and Bio security Nick Nwankpa, Karim Tounkara and Charles Bodjo OUTLINE OF PRESENTATION 1. INTRODUCTION 2. DEFINITIONS
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationValneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013
Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants
More informationSingle Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography
www.natrixseparations.com Complex Separations Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography AN1000 Summary Recombinant Shiga toxin
More informationGuidance for Industry
Guidance for Industry Q5A Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin U.S. Department of Health and Human Services Food and Drug Administration Center
More informationSabin-IPV Development
Sabin-IPV Development 9th WHO-UNICEF Informal Consultation with OPV & IPV Manufacturers & NRAs 02 December 2010, Geneva Wilfried Bakker 02 December 2010 WAM Bakker - Sabin-IPV Development 1 Contents Presentation
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationMycoplasma Testing Products & Services. M-175 CELLshipper Mycoplasma Detection Kit (In-house sample preparation and slide fixation)
Cell Culture Testing M-1500 Real-Time PCR with Broth Enrichment A specific and sensitive method for the detection of mycoplasma using Real-Time PCR coupled with a pre-enrichment procedure to enhance method
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationHow single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
More informationHigh yield antibody production in a disposable WAVE Bioreactor
High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),
More informationViruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope
Viruses Chapter 10: Viruses Lecture Exam #3 Wednesday, November 22 nd (This lecture WILL be on Exam #3) Dr. Amy Rogers Office Hours: MW 9-10 AM Too small to see with a light microscope Visible with electron
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.
ACCESS TO THE SEASONAL FLU VACCINE IN CANADA How the flu shot makes its way from the laboratory to the doctor s office. Health Canada is the federal department responsible for helping Canadians maintain
More informationAbout Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR
About Our Products Purified Infectious/Inactivated Agents ABI produces a variety of specialized reagents, allowing researchers to choose the best preparations for their studies. Available reagents include
More informationApplication Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary
Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,
More informationProposed replacement of TRS 878, Annex 1. World Health Organization 2010
ENGLISH ONLY FINAL Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks Proposed replacement
More informationInfluenza and Pandemic Flu Guidelines
Influenza and Pandemic Flu Guidelines Introduction Pandemic flu is a form of influenza that spreads rapidly to affect most countries and regions around the world. Unlike the 'ordinary' flu that occurs
More informationPandemic influenza preparedness Framework. for the sharing of influenza viruses and access to vaccines and other benefits
Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits Pandemic influenza preparedness Framework for the sharing of influenza viruses
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More informationImproving GS-CHO Cell Line Selection: Reducing Time to Clinic
Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters
More informationCALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com
CALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com ENGINEERING A PIVOTAL ROLE IN BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES
More informationRisk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationCHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use London, 24 July 2008 Doc. Ref. EMEA/CHMP/BWP/398498/2005 CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL
More informationSession 4: Attracting Investments and Generating Revenue Theory, Practice and Existing Business Models
Session 4: Attracting Investments and Generating Revenue Theory, Practice and Existing Business Models Case studies How does flu differ from other vaccines and how this affects marketing? Bio Farma: government
More informationBiopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?
BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz
More informationThe Production of Recombinant Factor VIII Process Design Project Final Report
The Production of Recombinant Factor VIII Process Design Project Final Report ChemE 250A, Final Report November 25, 2003 Matthew Avery Katie Plzak Jon Gass Table of Contents 1. INTRODUCTION...3 1.1 Product,
More informationAdjuvant Development for IPV. Martin Friede Ph.D. Initiative for Vaccine Research
Adjuvant Development for IPV Martin Friede Ph.D. Initiative for Vaccine Research Role of adjuvants in vaccine development Enable subunit antigens to induce protective immune response Achieve protective
More information3 Chapter Three: Material and methods (clone creation, upstream and downstream process)
3 Chapter Three: Material and methods (clone creation, upstream and downstream process) 3.1 Model proteins and CHO cell cultures Two recombinant produced, CHO-cell-derived model-glycoproteins, a less glycosylated
More informationVIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN Q5A(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS
More information50 g 650 L. *Average yields will vary depending upon a number of factors including type of phage, growth conditions used and developmental stage.
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Phage DNA Isolation Kit Product # 46800, 46850 Product Insert
More informationEXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015
0 0 0 WHO/BS/0. ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, to October 0 WHO GMP for Biological Products Proposed replacement of: TRS, Annex NOTE: This document has been prepared
More informationMichigan Department of State Police Emergency Management Division. Volume: 06-06 February 23, 2006
Michigan Department of State Police Emergency Management Division Informational Letter 4000 Collins Road P.O. Box 30636 Lansing, MI 48909-8136 www.michigan.gov/emd Volume: 06-06 February 23, 2006 TO: SUBJECT:
More informationQbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins
QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins 2015. 06. 09 Green Cross Corp. Green Cross Research Center Yong Jae Kim (YJKIM@greencross.com) Biologics World
More informationDr Ali A. Mohammadi President Global Health and Security Consultants. 18/3/2013 Global Health & Security Consultants
Dr Ali A. Mohammadi President Global Health and Security Consultants 18/3/2013 Global Health & Security Consultants Contents of presentation Definition Biosafety & Biosecurity considerations and principles
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationH1N1 SWINE FLU PANDEMIC
H1N1 SWINE FLU PANDEMIC 2 PANDEMIC H1N1 SWINE FLU Pandemic H1N1 Swine flu A novel influenza A H1N1 virus emerged from Mexico in April 2009 and spread so rapidly that the World Health Organisation declared
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationBuilding a business case for a fully continuous biomanufacturing platform
Building a business case for a fully continuous biomanufacturing platform Sol Pompe disease Argentina Integrated Continuous Biomanufacturing Jason Walther 23 October 2013 www.genzyme.com Fully continuous
More informationSCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production
A Technical Publication of SCANTIBODIES Laboratory, Inc. Volume 1 Number 4 9336 Abraham Way Santee, CA 92071 USA (619) 258-9300 fax (619) 258-9366 www.scantibodies.com SCANTIBODIES Laboratory, Inc. Contract
More informationFMD vaccines and vaccination in India; Production, use and quality. V.A.Srinivasan Research Director Indian Immunologicals Limited Hyderabad 500 032
FMD vaccines and vaccination in India; Production, use and quality V.A.Srinivasan Research Director Indian Immunologicals Limited Hyderabad 500 032 1. FMD vaccine production in India 2. Limitations in
More information